Form 4: Ligand Pharmaceuticals CFO Octavio Espinoza Reports Stock Transactions
SEC Form 4 Filing
Octavio Espinoza, CFO of Ligand Pharmaceuticals, reports acquisition and disposal of common stock related to vesting of performance and restricted stock units.
Summary
- On February 14, 2025, Octavio Espinoza, Chief Financial Officer of Ligand Pharmaceuticals, acquired 5,429 shares of common stock upon the vesting of performance stock units (PSUs) and 7,390 shares of common stock upon the vesting of performance stock units (PSUs).
- Also on February 14, 2025, 2,757 shares were disposed of to cover tax liabilities related to the settlement of performance stock units at a price of $120.
- On February 15, 2025, a total of 3,027 shares were disposed of to cover tax liabilities related to the settlement of restricted stock units at a price of $120.
- Following these transactions, Espinoza directly owns 23,879 shares of Ligand Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions, with neutral sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they relate to executive compensation and do not indicate a change in the company's fundamentals.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Acquisition of 5,429 shares of common stock upon vesting of performance stock units (PSUs). |
| 02/14/2025 | Disposal of 2,757 shares for tax liabilities related to PSU settlement at $120 per share. |
| 02/14/2025 | Acquisition of 7,390 shares of common stock upon vesting of performance stock units (PSUs). |
| 02/15/2025 | Disposal of 3,027 shares for tax liabilities related to restricted stock unit settlement at $120 per share. |
| 02/19/2025 | Date of signature for the report. |
Keywords
Ligand Pharmaceuticals, Octavio Espinoza, Form 4, Stock Transactions, CFO, PSU, RSU
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.